Ascentage Pharma Announces First Patient Dosed in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 as Single Agent and in Combinations for the Treatment of Hematologic Malignancies in China

On July 22, 2020 Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, reported that the Phase Ib study of the company’s novel MDM2-p53 inhibitor candidate APG-115 as a single agent or in combinations for the treatment of Chinese patients with relapsed/refractory acute myeloid leukemia (r/r AML), or relapsed/progressed high/very high risk myelodysplastic syndrome (MDS) has dosed its first patient in China (Press release, Ascentage Pharma, JUL 22, 2020, View Source [SID1234562241]). As the first MDM2-p53 inhibitor entering clinical studies for the treatment of solid tumors in China, this is the first study of APG-115 in patients with hematologic malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This multicenter Phase Ib clinical study in China is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of APG-115 as a single agent or in combination with azacitidine or cytarabine in patients with hematologic malignancies, including r/r AML and relapsed/progressed high/very high risk MDS.

AML is a clonal proliferative disease of the bone marrow, of which the incidence rate increases with age. AML is the most common type of leukemia in China, with an incidence rate of 1.62-2.32 cases per 100,0001. The standard induction therapy for AML comprises the "7+3" regimen (7 days of cytarabine plus 3 days of anthracycline drugs), but up to 40% of newly diagnosed AML patients do not achieve complete response (CR) during initial induction therapy, which is considered as refractory, or relapse within 6 months after achieving CR2.

MDS is a heterogeneous hematopoietic disease caused by abnormal pluripotent stem cells, and the condition is characterized by poor hematopoietic function, bone marrow failure, reduction in peripheral blood cells, and reduced survival rates. The incidence rate of MDS in China is approximately 5 cases per 100,000. Although hypomethylating agents can produce a high response rate in patients with MDS, many patients eventually develop drug resistance to hypomethylating agents. Patients who have developed the acquired drug resistance commonly face a very poor prognosis. In patients with high-risk MDS, treatment failure with hypomethylating agents is associated with an average survival of less than 6 months3. As a result, both refractory/progressed AML and MDS represent an urgent medical need for more effective therapies.

APG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2-p53 protein-protein interaction (PPI). APG-115 has strong binding affinity to MDM2 and is designed to activate tumor suppression activity of p53 by blocking the MDM2-p53 PPI. APG-115 is the first MDM2-p53 inhibitor entering clinical development in China, with multiple ongoing clinical studies in solid tumors in China and the US. At present, APG-115 is being investigated in a range of hematologic malignancies globally.

"Currently, there remains to be significant unmet medical needs in the treatment of hematologic malignancies, including AML and MDS," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "We have also noticed that drug development targeting the MDM2-p53 pathway has received growing interest. As the first MDM2-p53 inhibitor entering clinical study in China, APG-115 has already demonstrated favorable safety profiles and preliminary efficacy in solid tumors. We will actively explore APG-115’s therapeutic potential in hematologic malignancies, to hopefully provide more options of AML and MDS treatment to patients in China and around the world."

References:

1.Chang R, Wu S, Chen W, et al. Analysis on epidemiological characteristics of leukemia in Gansu Province from 2003 to 2012 [Article in Chinese]. Modern Preventive Med. 2014;41(21):3841-04.

2.Thol F, Schlenk RF, Heuser M, Ganser A. 2015. How I treat refractory and early relapsed acute myeloid leukemia. Blood 126: 319-27

3.Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, et al. 2011. Outcome of high-risk myelodysplastic syndrome after Azacitidine treatment failure. J Clin Oncol 29: 3322-7

About APG-115

APG-115 is an orally administered, selective, small-molecule inhibitor of the MDM2-p53 PPI. APG-115 has strong binding affinity to MDM2 and is designed to activate p53 tumor suppression activity by blocking the MDM2-p53 PPI. Ascentage Pharma has previously commenced three clinical trials of APG-115 in the US, including a Phase I study as single agent, a Phase Ib/II study in combination with pembrolizumab for treatment of metastatic melanoma and other advanced solid tumors, and a Phase I/II study as a single agent or in combination with chemotherapy for treatment of salivary gland cancer. APG-115 is the first MDM2-p53 inhibitor to enter clinical studies in China. A Phase I study as a single agent, and a Phase Ib study as a single agent or in combination with chemotherapy for treatment of AML (acute myeloid leukemia) or MDS (myelodysplastic syndrome) are ongoing in China.

CURE Media Group Expands Its Strategic Alliance Partnership Program With GO2 Foundation for Lung Cancer

On July 22, 2020 CURE Media Group, which reaches over 1 million patients, survivors and caregivers across an industry-leading multimedia platform devoted solely to cancer updates and research, reported the addition of the GO2 Foundation for Lung Cancer to its Strategic Alliance Partnership (SAP) program (Press release, GO2 Foundation, JUL 22, 2020, View Source [SID1234562258]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited and proud to partner with the GO2 Foundation for Lung Cancer," said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of CURE Media Group. "They work to empower the lung cancer community to help improve care, increase survivorship and drive advocacy for awareness of the disease."

The GO2 Foundation for Lung Cancer was founded by lung cancer patients and survivors and is the world’s leading organization dedicated to saving, extending and improving the lives of those vulnerable, at risk and diagnosed with lung cancer. The foundation strives to change the reality of living with lung cancer by ending stigma about the disease, increasing public and private research funding, and ensuring access to care.

"We are proud to continue to work alongside CURE Media Group to educate, inform, support, and bring hope to the lung cancer community," said Laurie Fenton Ambrose, co-founder, president and CEO of GO2 Foundation for Lung Cancer. "Every patient and caregiver matters, and this partnership allows us to extend our life-saving efforts to a broader community. We live up to our mantra of Whatever it takes. Whatever the need. We get it done together."

The SAP program builds a community of advocacy groups, medical associations and medical institutions to foster collaboration and an open exchange of information among trusted peers for the ultimate benefit of patients and their families. As part of this joint effort, CURE Media Group will work with the GO2 Foundation for Lung Cancer to share exclusive content and support the lung cancer community.

CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock

On July 22, 2020 CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, reported the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a price to the public of $1.90 per share. CASI has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock (Press release, CASI Pharmaceuticals, JUL 22, 2020, View Source [SID1234562242]). The offering is expected to close on or about July 24, 2020, subject to satisfaction of customary closing conditions. The gross proceeds to CASI from the offering, excluding any exercise by the underwriters of their 30-day option to purchase additional shares, are expected to be approximately $38.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by CASI.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer & Co. Inc. is acting as the sole bookrunning manager, and Brookline Capital Markets, a division of Arcadia Securities, LLC is acting as co-manager, for the offering.

CASI intends to use the net proceeds of the offering for working capital and general corporate purposes, which include, but are not limited to advancing our product portfolio, acquiring the rights to new product candidates and general and administrative expenses.

The securities described above are being offered by CASI pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed on December 13, 2017 and declared effective by the U.S. Securities and Exchange Commission ("SEC") on December 22, 2017. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at (212) 667-8055, or by email at [email protected].

Before investing in the offering, you should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that CASI has filed with the SEC that are incorporated by reference in the preliminary prospectus supplement and the accompanying prospectus, which provide more information about CASI and the offering.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Ultivue and OracleBio partner to help advance personalized tumor characterization and clinical oncology research using multiplex immunofluorescence

On July 22, 2020 Ultivue, Inc. reported a collaborative partnership with OracleBio to help further insights and advance personalized tumor characterization in translational and clinical oncology research and drug development using multiplex immunofluorescence staining and imaging (Press release, Ultivue, JUL 22, 2020, View Source [SID1234562259]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The deal connects the histopathology image analysis expertise of OracleBio and the tissue staining capabilities of Ultivue, with the goal of providing pharmaceutical companies with an end-to-end workflow for gaining valuable insights from biomarkers in situ.

OracleBio, a contract research organization based in Scotland, is known for its quantitative digital pathology services, delivering high-quality image analysis while leveraging multiple software platforms in supporting clinical and pre-clinical research.

"OracleBio aim to deliver robust quantitative histopathology data deployed within a quality framework, and that analysis can be heavily dependent on the quality of sample preparation and staining," says Lorcan Sherry, CSO of OracleBio. "Being able to partner with Ultivue means we can be confident in the staining of the tissue we’re quantifying, which ultimately means more precise data."

The Cambridge, Massachusetts-based Ultivue develops reagents for staining tissues used for multiplex immunofluorescence imaging and analysis. Its proprietary InSituPlex technology is designed for fast and comprehensive exploration of biologically-relevant markers in tissue samples.

"We’ve developed reagents that are workflow-agnostic and can plug-and-play in most customers’ existing laboratory infrastructure, so it makes sense to partner with a like-minded imaging and analysis CRO like you have in OracleBio. At the end of the day, our goal is always to offer our customers relevant and meaningful biological insights from their samples, regardless of their preferred hardware or software," says Jacques Corriveau, President and CEO of Ultivue.

BioInvent’s BI-1206 could improve treatment in several cancers

On June 22, 2020 BioInvent reported that Alexander Eggermont, MD, PhD, Chief Scientific Officer at the Princess Máxima Center and renowned expert in immunotherapy showcased the broad potential of BI-1206 in enhancing checkpoint inhibitors in solid cancers in a KOL event hosted by BioInvent on July 21 (Press release, BioInvent, JUL 22, 2020, View Source [SID1234562260]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Professor Eggermont discussed the clinical challenges associated with the use of checkpoint inhibitors in solid tumors and the potential for an enhanced response with immune-modulatory antibodies, specifically those targeting FcγRIIB, such as BI-1206.

"The most important message to take away from this presentation – BI-1206 has the potential to go across multiple tumor types, much like pembrolizumab which is approved in over 20 different cancer types," said professor Eggermont.

BioInvent’s lead pipeline candidate BI-1206 is a first-in-class monoclonal antibody that targets FcγRIIB – the only inhibitory Fcγ receptor that acts as a "brake" on the innate immune system – to unleash antibody-mediated reactivation of the immune response against cancer.

"We are thrilled with the strong support for the potential broad use of BI-1206 in many different cancers from such a renowned expert as professor Eggermont," said Martin Welschof, CEO of BioInvent.

Professor Eggermont highlighted three main advantages of BI-1206.

To begin with, BI-1206 can give better and prolonged anti-PD1 blocking and thus, it has the potential to be used in many first line indications across multiple tumor types.

Furthermore, BI-1206 can overcome resistance to anti-PD1. It enhances the activity of, for example rituximab and overcomes resistance to those agents. It is an enhancer that has potential to go across multiple tumor types in refractory settings by blocking FcγRIIB interaction.

Last but not least. Dosing of BI-1206 may be different in 1st and 2nd line and be different in different tumor types. BI-1206 can be optimized and dosed as needed which gives a big potential for a wide development pathway.

"The simplicity of the BI-1206 model is very attractive. BI-1206 has an additive or synergistic, further enhancement of anti-PD-1 function. It has tremendous potential as it can be used in multiple indications," concluded professor Eggermont.

For further detail please listen to the call: link

Prof. Alexander M.M. Eggermont, MD, PhD is an internationally recognized expert in surgical oncology, immunotherapy, melanoma, sarcoma and cancer drug development. He currently holds roles as Chief Scientific Officer at the Princess Máxima Center for Pediatric Oncology, the Netherlands; Professor of Oncology (Classe Exceptionelle) at Paris-Saclay University, France; Coordinator, Comprehensive Cancer Center Program for Deutsche KrebsHilfe; and Strategic Advisor at the German Cancer Consortium (DKFZ).

Prof. Eggermont was previously Director General of Gustave Roussy Comprehensive Cancer Center, Villejuif, France (2010-2019); and Professor of Surgical Oncology (2003-2016) and Endowed Professor of International Networking in Cancer Research (2011-2018) at Erasmus University MC, Rotterdam, the Netherlands. He holds a PhD in tumor immunology from Erasmus University and is Fellow of the National Institutes of Health’s National Cancer Institute (NIH-NCI). Prof. Eggermont has served as President of ECCO, President of the EORTC, was a member of the Board of Directors of ASCO (Free ASCO Whitepaper), served on the Editorial Board of the Journal of Clinical Oncology, and is currently Editor-in-Chief of the European Journal of Cancer. Prof. Eggermont has published more than 900 peer-reviewed papers and his expertise has been acknowledged by many professional awards throughout his career.